Achilles Therapeutics plc (NASDAQ:ACHL) Sees Large Increase in Short Interest

Achilles Therapeutics plc (NASDAQ:ACHL) was the target of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 122,300 shares, a growth of 35.4% from the December 15th total of 90,300 shares. Based on an average daily volume of 169,400 shares, the short-interest ratio is presently 0.7 days. Approximately 0.3% of the company’s shares are short sold.

Achilles Therapeutics Stock Performance

NASDAQ ACHL opened at $1.14 on Friday. Achilles Therapeutics has a fifty-two week low of $0.63 and a fifty-two week high of $1.76. The stock has a market cap of $46.85 million, a P/E ratio of -0.69 and a beta of 1.32. The stock has a 50 day simple moving average of $1.08 and a two-hundred day simple moving average of $0.94.

Institutional Trading of Achilles Therapeutics

An institutional investor recently raised its position in Achilles Therapeutics stock. XTX Topco Ltd grew its stake in Achilles Therapeutics plc (NASDAQ:ACHL) by 239.4% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 51,660 shares of the company’s stock after purchasing an additional 36,441 shares during the quarter. XTX Topco Ltd owned about 0.13% of Achilles Therapeutics worth $42,000 at the end of the most recent quarter. 56.38% of the stock is owned by institutional investors.

Achilles Therapeutics Company Profile

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.